EICHOR
● Active Not Recruiting
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Condition: Epithelial Ovarian Cancer · Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Sponsor: Klus Pharma Inc.
About this study
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma 10. Cervical cancer
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (109)
| Los Angeles Hematology Oncology Medical Group | Glendale, California, United States | — |
| University of California Los Angeles | Los Angeles, California, United States | — |
| Florida Cancer Specialists and Research Institute | Sarasota, Florida, United States | — |
| START MidWest | Grand Rapids, Michigan, United States | — |
| The University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States | — |
| Oklahoma Cancer Specialists and Research Institute, LLC | Tulsa, Oklahoma, United States | — |
| Providence Cancer Institute, Franz Clinic | Portland, Oregon, United States | — |
| Mary Crowley Cancer Research | Dallas, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | — |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | — |
| Sunnybrook Research Institute | Toronto, Ontario, Canada | — |
+ 97 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04152499